RxDoctor Payments Data

Ajay Labroo

Interventional Cardiology · Panama City, FLNPI 1831199371

Payments from drug & device makers

$16,216in general payments, 2019–2025

Across 194 payments — averaging $83.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$6K
  • AstraZeneca$5K
  • Kowa Research Institute, Inc.$1K
  • Actelion Pharmaceuticals US, Inc.$702
  • Merck$701
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$450
  • plus $2K from 22 others

What the payments were for

  • Speaking & faculty fees$4,95052%
  • Travel & lodging$1091%
  • Food & beverage$4,30945%
  • Education$1992%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,216 in reported general payments places this provider in the 60th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$117,390
Medicare patients
470
Services billed
1,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag17$388,050
EntrestoSacubitril/Valsartan18$22,706
EliquisApixaban12$16,658
Metoprolol Succinate44$887
Ramipril21$282
Atorvastatin Calcium24$268
Losartan Potassium22$220
Carvedilol29$182
Spironolactone17$180
ClopidogrelClopidogrel Bisulfate33$158
Amlodipine Besylate25$138
Nitroglycerin11$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi$702$388,05017 claims
NovartisEntresto$5,680$22,70618 claims
PfizerEliquis$54$16,65812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →